RANCHO CUCAMONGA, Calif. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2018 ended June 30, 2018 , after the market closes on Wednesday, August 8, 2018 , and will hold a conference call to
RANCHO CUCAMONGA, Calif. , July 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced business expansion plans for its subsidiary, Amphastar Nanjing Pharmaceuticals Inc. (“ANP”). To date, ANP has provided Active Pharmaceutical Ingredients (“APIs”) and starting
RANCHO CUCAMONGA, Calif. , June 19, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. , (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has granted approval of its abbreviated new drug application (“ANDA”) for Isoproterenol Hydrochloride Injection, USP 0.2mg/mL,
RANCHO CUCAMONGA, Calif. , June 04, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters , CFO, will be presenting at the Jefferies Healthcare Conference on Tuesday, June 5, 2018 at 3:00 p.m. Eastern Time in New York, NY .
RANCHO CUCAMONGA, Calif. , June 04, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) granted approval of the company’s abbreviated new drug application (“ANDA”) supplement for the manufacture of semi-purified heparin
RANCHO CUCAMONGA, Calif. , May 14, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) granted approval of the company’s abbreviated new drug application (“ANDA”) for Calcium Chloride injection 10% in the 10 mL Luer-Jet
RANCHO CUCAMONGA, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell , President, and Bill Peters , CFO, will be presenting at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 15, 2018 at 1:00 p.m.
Reports Net Revenues of $58.4 Million for the Three Months Ended March 31, 2018 RANCHO CUCAMONGA, Calif. , May 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2018 .
RANCHO CUCAMONGA, Calif. , May 03, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2018 ended March 31, 2018 , after the market closes on Wednesday, May 9, 2018 , and will hold a conference call to
RANCHO CUCAMONGA, Calif. , March 26, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters , CFO will be presenting at the Needham‘s 17 th Annual Healthcare Conference on Wednesday, March 28, 2018 at 9:30 a.m. Eastern Time in New York, NY .
